Cost-Effectiveness of Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review of Cost-Effectiveness Studies for the American College of Physicians
Authors' conclusion
Glucagon-like peptide-1 agonists and SGLT2i are of low value as first-line therapy but may be of intermediate value when added to metformin or other background therapy compared with adding nothing. Other drugs and comparisons are of low or uncertain value. Results are sensitive to drug effectiveness and cost assumptions.
Study context
- Population
- Adults with T2D; U.S.-perspective cost-effectiveness analyses (CEAs) estimating cost per quality-adjusted life-year (QALY), 1 January 2010 to 13 July 2023, English9 CEAs
- Comparison
- Newer antidiabetes medications vs metformin, SU, neutral protamine Hagedorn (NPH) insulin and others
- Outcome
- Cost per QALY gained: low (>$150 000), intermediate ($50 to $150 000) or high (<$50 000) value
Methodological detailsU.S. perspective, GRADE certainty of evidence, Drummond criteria risk of bias
- U.S. perspective
- GRADE certainty of evidence
- Drummond criteria risk of bias
Pooled result
As reported in the abstract
Value (cost per QALY)
- GLP1a and SGLT2i vs metformin as first-line therapy: low value (high CoE)
- GLP1a and SGLT2i added to metformin or background therapy vs adding nothing: may be intermediate value (low CoE)
- Insulin analogues vs NPH insulin: may be similarly effective but more expensive (low CoE)
- GIP/GLP1a value uncertain (insufficient CoE)
Further pooled results
Risk of bias of included CEAs
- Low risk of bias (RoB)
- 2
- High RoB
- 1
- Some concerns RoB
- 6
Original publication
Cost-Effectiveness of Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review of Cost-Effectiveness Studies for the American College of Physicians. Ann Intern Med. Published 19 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →